[
  {
    "ts": null,
    "headline": "Moderna is most shorted stock in S&P 500 as Americans skip immunizations",
    "summary": "Vaccine-maker Moderna has become the most shorted company in the S&P 500, with its share price slumping to its lowest level since before the...",
    "url": "https://finnhub.io/api/news?id=32a8b2d213cd3c1b0236941284732a8562288d77da8df68e949eb010b4b199c7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763899205,
      "headline": "Moderna is most shorted stock in S&P 500 as Americans skip immunizations",
      "id": 137587087,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Vaccine-maker Moderna has become the most shorted company in the S&P 500, with its share price slumping to its lowest level since before the...",
      "url": "https://finnhub.io/api/news?id=32a8b2d213cd3c1b0236941284732a8562288d77da8df68e949eb010b4b199c7"
    }
  },
  {
    "ts": null,
    "headline": "How Recent Developments Are Rewriting the Story for Moderna",
    "summary": "Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This change reflects revised expectations for the company's long-term potential. The adjustment comes as revenue growth projections have been reduced from 18.75% to 10.31%, with analysts weighing bullish signals against lingering macro and operational challenges. Stay tuned to discover how investors can stay ahead of these evolving perspectives on Moderna's future...",
    "url": "https://finnhub.io/api/news?id=ec448de7714f4d3a508e8bc33465fa63e08f1222009761e3676ea1cc06e923a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763874514,
      "headline": "How Recent Developments Are Rewriting the Story for Moderna",
      "id": 137587088,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRNA",
      "source": "Yahoo",
      "summary": "Moderna’s stock has seen a notable shift in sentiment after its fair value estimate was cut from $40.30 to $37.32. This change reflects revised expectations for the company's long-term potential. The adjustment comes as revenue growth projections have been reduced from 18.75% to 10.31%, with analysts weighing bullish signals against lingering macro and operational challenges. Stay tuned to discover how investors can stay ahead of these evolving perspectives on Moderna's future...",
      "url": "https://finnhub.io/api/news?id=ec448de7714f4d3a508e8bc33465fa63e08f1222009761e3676ea1cc06e923a5"
    }
  }
]